BNP PARIBAS ASSET MANAGEMENT Holding S.A. Acquires New Position in Blueprint Medicines Co. (NASDAQ:BPMC)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 69,887 shares of the biotechnology company's stock, valued at approximately $6,465,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.11% of Blueprint Medicines as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of BPMC. Advisors Asset Management Inc. raised its position in shares of Blueprint Medicines by 17.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 5,054 shares of the biotechnology company's stock worth $467,000 after purchasing an additional 756 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Blueprint Medicines in the third quarter worth $475,000. Segall Bryant & Hamill LLC increased its position in Blueprint Medicines by 11.6% in the third quarter. Segall Bryant & Hamill LLC now owns 141,622 shares of the biotechnology company's stock worth $13,100,000 after buying an additional 14,668 shares during the period. Swiss National Bank boosted its holdings in shares of Blueprint Medicines by 1.6% during the third quarter. Swiss National Bank now owns 116,200 shares of the biotechnology company's stock valued at $10,748,000 after acquiring an additional 1,800 shares during the period. Finally, S&CO Inc. grew its position in shares of Blueprint Medicines by 49.3% during the third quarter. S&CO Inc. now owns 10,000 shares of the biotechnology company's stock worth $925,000 after acquiring an additional 3,300 shares during the last quarter.

Insider Buying and Selling at Blueprint Medicines

In other news, insider Fouad Namouni sold 3,633 shares of the firm's stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares of the company's stock, valued at $6,169,332.40. This trade represents a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 4.21% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Wells Fargo & Company cut their price objective on shares of Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating on the stock in a research report on Thursday, October 31st. UBS Group began coverage on Blueprint Medicines in a report on Thursday, October 24th. They set a "neutral" rating and a $88.00 price target on the stock. Barclays increased their price objective on Blueprint Medicines from $75.00 to $105.00 and gave the stock an "equal weight" rating in a report on Monday, July 29th. Needham & Company LLC reaffirmed a "buy" rating and set a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, November 15th. Finally, HC Wainwright reiterated a "buy" rating and set a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, November 15th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Blueprint Medicines presently has a consensus rating of "Moderate Buy" and an average price target of $122.11.

Blueprint Medicines Price Performance

Shares of NASDAQ BPMC traded down $0.28 during trading on Monday, hitting $93.87. The company had a trading volume of 734,430 shares, compared to its average volume of 692,903. The company has a market cap of $5.96 billion, a P/E ratio of -44.49 and a beta of 0.59. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The business's 50-day moving average is $90.51 and its 200 day moving average is $98.36. Blueprint Medicines Co. has a 52 week low of $67.00 and a 52 week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.97) by $0.08. The company had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. Blueprint Medicines's revenue for the quarter was up 126.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.20) earnings per share. Equities research analysts predict that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.